Project Grant HT94252310416
Award Date
9/1/23
Completion Date
8/31/27
Dollars Obligated
$596K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
Brigham & Women's Hospital Inc. was awarded a $1,859,665 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 to August 31, 2027 to investigate environmental and gut-brain axis determinants of cognitive outcomes in Parkinson's disease. As the primary awardee, Brigham & Women's Hospital will leverage its expertise in biomedical research to advance understanding of how...
Brigham & Women's Hospital Inc. was awarded a $379,876 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2023 through August 31, 2026 to investigate whether microbiome-derived cell fragments in the brain can accelerate the transition from traumatic brain injury to Alzheimer's disease or related dementias. As the direct awardee, Brigham & Women's Hospital will leverage...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
This Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $566,810.00 to Brigham & Women's Hospital Inc., a non-profit hospital and research institution in Boston, MA, to support research on the neural regulation of small cell lung cancer progression. The award period is from September 1, 2023 to August 31, 2025. Brigham & Women's Hospital Inc. has previously conducted biomedical research and provided...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The Defense Health Agency awarded a $772,626 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, effective from August 1, 2025 to July 31, 2028, will fund preclinical validation of gene therapy in mouse models of tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM). Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston,...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
The Defense Health Agency awarded a $864,498 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Brigham & Women's Hospital Inc. for a project titled "TARGETING NEUROINFLAMMATION TO PROMOTE NEUROLOGICAL RECOVERY AFTER TRAUMATIC SPINAL CORD INJURY". The project period runs from August 1, 2025 to July 31, 2028. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution affiliated with Harvard Medical...
The $925,344 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to Brigham & Womens Hospital Inc. will support research to "MODULATE MICROGLIA AND ASTROCYTES TO TREAT ALZHEIMER'S DISEASE AND RELATED DEMENTIAS". The 3-year grant, awarded on April 15, 2024, will fund innovative biomedical research focused on developing new treatments for Alzheimer's disease and other neurodegenerative conditions by investigating the...
Brigham & Women's Hospital Inc. was awarded a $1,523,784 Project Grant from the Department of the Army Medical Command's Military Medical Research and Development program to investigate cytoplasmic DNA-sensing pathways in BRCA1-deficient breast cancer development. The three-year award beginning July 1, 2022 will support research into medical solutions for breast cancer at the cellular level through studying the role of cytoplasmic DNA sensors in breast cancer tumor growth associated with...